A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir +/- Ribavirin for GT1 Subjects with Chronic Hepatitis C previously treated with an NS5A Inhibitor + Sofosbuvir Therapy? (Protocol number B16-439; or DAA-SALVAGE
|Effective start/end date||3/20/17 → 12/31/18|
- University of Florida
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.